228 related articles for article (PubMed ID: 17606205)
21. Model for end-stage liver disease (MELD) exception for portopulmonary hypertension.
Krowka MJ; Fallon MB; Mulligan DC; Gish RG
Liver Transpl; 2006 Dec; 12(12 Suppl 3):S114-6. PubMed ID: 17123283
[No Abstract] [Full Text] [Related]
22. Model for end-stage liver disease (MELD) exception for hepatopulmonary syndrome.
Fallon MB; Mulligan DC; Gish RG; Krowka MJ
Liver Transpl; 2006 Dec; 12(12 Suppl 3):S105-7. PubMed ID: 17123282
[No Abstract] [Full Text] [Related]
23. Liver transplantation in the era of model for end-stage liver disease.
Wang VS; Saab S
Liver Int; 2004 Feb; 24(1):1-8. PubMed ID: 15101994
[TBL] [Abstract][Full Text] [Related]
24. Model for end-stage liver disease (MELD) exception for uncommon hepatic tumors.
Punch J; Gish RG
Liver Transpl; 2006 Dec; 12(12 Suppl 3):S122-3. PubMed ID: 17123279
[No Abstract] [Full Text] [Related]
25. Model for end-stage liver disease (MELD) exception for portal hypertensive gastrointestinal bleeding.
Sheiner P; Gish RG; Sanyal A
Liver Transpl; 2006 Dec; 12(12 Suppl 3):S112-3. PubMed ID: 17123290
[No Abstract] [Full Text] [Related]
26. Model for end-stage liver disease (MELD) exception for cholangiocarcinoma or biliary dysplasia.
Gores GJ; Gish RG; Sudan D; Rosen CB;
Liver Transpl; 2006 Dec; 12(12 Suppl 3):S95-7. PubMed ID: 17123289
[No Abstract] [Full Text] [Related]
27. Clinically relevant differences in the model for end-stage liver disease and model for end-stage liver disease-sodium scores determined at three university-based laboratories of the same area.
Xiol X; Gines P; Castells L; Twose J; Ribalta A; Fuentes-Arderiu X; Rodriguez S; Castellote J; Navasa M; Deulofeu R
Liver Transpl; 2009 Mar; 15(3):300-5. PubMed ID: 19242993
[TBL] [Abstract][Full Text] [Related]
28. Model for end-stage liver disease (MELD) exception guidelines: results and recommendations from the MELD Exception Study Group and Conference (MESSAGE) for the approval of patients who need liver transplantation with diseases not considered by the standard MELD formula.
Freeman RB; Gish RG; Harper A; Davis GL; Vierling J; Lieblein L; Klintmalm G; Blazek J; Hunter R; Punch J
Liver Transpl; 2006 Dec; 12(12 Suppl 3):S128-36. PubMed ID: 17123284
[No Abstract] [Full Text] [Related]
29. MELD-based liver allocation: who is underserved?
Biggins SW; Bambha K
Semin Liver Dis; 2006 Aug; 26(3):211-20. PubMed ID: 16850370
[TBL] [Abstract][Full Text] [Related]
30. Aetiology of cirrhosis of the liver has an impact on survival predicted by the Model of End-stage Liver Disease score.
Angermayr B; Luca A; König F; Bertolini G; Ploner M; Gridelli B; Ulbrich G; Reiberger T; Bosch J; Peck-Radosavljevic M
Eur J Clin Invest; 2009 Jan; 39(1):65-71. PubMed ID: 19087131
[TBL] [Abstract][Full Text] [Related]
31. Impact of the MELD score on waiting time and disease severity in liver transplantation in United States veterans.
Ahmad J; Downey KK; Akoad M; Cacciarelli TV
Liver Transpl; 2007 Nov; 13(11):1564-9. PubMed ID: 17969210
[TBL] [Abstract][Full Text] [Related]
32. MELD-based allocation scheme for liver transplantation in Israel.
Onaca N; Mor E
Isr Med Assoc J; 2006 Sep; 8(9):651-2. PubMed ID: 17058421
[No Abstract] [Full Text] [Related]
33. Model for end-stage liver disease score-based allocation of donors for liver transplantation: a spanish multicenter experience.
de la Mata M; Cuende N; Huet J; Bernardos A; Ferrón JA; Santoyo J; Pascasio JM; Rodrigo J; Solórzano G; Martín-Vivaldi R; Alonso M
Transplantation; 2006 Dec; 82(11):1429-35. PubMed ID: 17164713
[TBL] [Abstract][Full Text] [Related]
34. Model for End-Stage Liver Disease (MELD) system to allocate and to share livers: experience of two Italian centers.
Ravaioli M; Masetti M; Dazzi A; Romano A; Spaggiari M; Grazi GL; Ercolani G; Cescon M; Di Gioia P; De Ruvo N; Montalti R; Ballarin R; Di Benedetto F; Ridolfi L; Alvaro N; Ramacciato G; Morelli C; Gerunda E; Pinna AD
Transplant Proc; 2008; 40(6):1814-5. PubMed ID: 18675057
[TBL] [Abstract][Full Text] [Related]
35. Model for End-Stage Liver Disease (MELD) score system to evaluate patients with viral hepatitis on the waiting list: better than the Child-Turcotte-Pugh (CTP) system?
Cuomo O; Perrella A; Arenga G
Transplant Proc; 2008; 40(6):1906-9. PubMed ID: 18675085
[TBL] [Abstract][Full Text] [Related]
36. Overview of the MELD/PELD system of liver allocation indications for liver transplantation in the MELD era: evidence-based patient selection.
Freeman RB
Liver Transpl; 2004 Oct; 10(10 Suppl 2):S2-3. PubMed ID: 15382218
[No Abstract] [Full Text] [Related]
37. [Model for end-stage liver disease (MELD) score and liver transplantation].
Zhang JY; Wang BE; Jia JD
Zhonghua Gan Zang Bing Za Zhi; 2005 Mar; 13(3):235-7. PubMed ID: 15760570
[No Abstract] [Full Text] [Related]
38. Comparison of four model for end-stage liver disease-based prognostic systems for cirrhosis.
Huo TI; Lin HC; Huo SC; Lee PC; Wu JC; Lee FY; Hou MC; Lee SD
Liver Transpl; 2008 Jun; 14(6):837-44. PubMed ID: 18508377
[TBL] [Abstract][Full Text] [Related]
39. Should we change the priority for liver allocation for patients with the highest MELD score?
Freeman RB; Wiesner R
Hepatology; 2012 Jan; 55(1):14-5. PubMed ID: 22095707
[No Abstract] [Full Text] [Related]
40. Model for the end-stage liver disease and death prediction in a cohort of Brazilian patients on the waiting list for liver transplantation.
Brandão A; Fuchs SC; Gleisner AL; Marroni C; Zanotelli ML; Cantisani G
Clin Transplant; 2008; 22(5):651-6. PubMed ID: 18549449
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
